BAJAJHCARE2025-07-012025-09-30BAJAJHCARE2025-09-30BAJAJHCARE2025-03-31BAJAJHCARE2025-04-012025-09-30BAJAJHCARE2025-07-012025-09-30in-capmkt:OtherExpenses1MemberBAJAJHCARE2025-07-012025-09-30in-capmkt:OtherExpenses2MemberBAJAJHCARE2025-07-012025-09-30in-capmkt:OtherExpenses3MemberBAJAJHCARE2025-07-012025-09-30in-capmkt:OtherExpenses4MemberBAJAJHCARE2025-07-012025-09-30in-capmkt:OtherExpenses5MemberBAJAJHCARE2025-07-012025-09-30in-capmkt:OtherExpenses6MemberBAJAJHCARE2025-07-012025-09-30in-capmkt:OtherExpenses7MemberBAJAJHCARE2025-07-012025-09-30in-capmkt:OtherExpenses8MemberBAJAJHCARE2025-07-012025-09-30in-capmkt:OtherExpenses9MemberBAJAJHCARE2025-07-012025-09-30in-capmkt:OtherExpenses10MemberBAJAJHCARE2025-04-012025-09-30in-capmkt:OtherExpenses1MemberBAJAJHCARE2025-04-012025-09-30in-capmkt:OtherExpenses2MemberBAJAJHCARE2025-04-012025-09-30in-capmkt:OtherExpenses3MemberBAJAJHCARE2025-04-012025-09-30in-capmkt:OtherExpenses4MemberBAJAJHCARE2025-04-012025-09-30in-capmkt:OtherExpenses5MemberBAJAJHCARE2025-04-012025-09-30in-capmkt:OtherExpenses6MemberBAJAJHCARE2025-04-012025-09-30in-capmkt:OtherExpenses7MemberBAJAJHCARE2025-04-012025-09-30in-capmkt:OtherExpenses8MemberBAJAJHCARE2025-04-012025-09-30in-capmkt:OtherExpenses9MemberBAJAJHCARE2025-04-012025-09-30in-capmkt:OtherExpenses10MemberBAJAJHCARE2025-07-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss1BAJAJHCARE2025-04-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss1BAJAJHCARE2025-07-012025-09-30RelatedPartyTransactionDomain1BAJAJHCARE2025-06-30RelatedPartyTransactionDomain1BAJAJHCARE2025-09-30RelatedPartyTransactionDomain1BAJAJHCARE2025-07-012025-09-30RelatedPartyTransactionDomain2BAJAJHCARE2025-06-30RelatedPartyTransactionDomain2BAJAJHCARE2025-09-30RelatedPartyTransactionDomain2BAJAJHCARE2025-07-012025-09-30RelatedPartyTransactionDomain3BAJAJHCARE2025-06-30RelatedPartyTransactionDomain3BAJAJHCARE2025-09-30RelatedPartyTransactionDomain3BAJAJHCARE2025-07-012025-09-30RelatedPartyTransactionDomain4BAJAJHCARE2025-06-30RelatedPartyTransactionDomain4BAJAJHCARE2025-09-30RelatedPartyTransactionDomain4BAJAJHCARE2025-07-012025-09-30RelatedPartyTransactionDomain5BAJAJHCARE2025-06-30RelatedPartyTransactionDomain5BAJAJHCARE2025-09-30RelatedPartyTransactionDomain5BAJAJHCARE2025-07-012025-09-30RelatedPartyTransactionDomain6BAJAJHCARE2025-06-30RelatedPartyTransactionDomain6BAJAJHCARE2025-09-30RelatedPartyTransactionDomain6BAJAJHCARE2025-07-012025-09-30RelatedPartyTransactionDomain7BAJAJHCARE2025-06-30RelatedPartyTransactionDomain7BAJAJHCARE2025-09-30RelatedPartyTransactionDomain7BAJAJHCARE2025-07-012025-09-30RelatedPartyTransactionDomain8BAJAJHCARE2025-06-30RelatedPartyTransactionDomain8BAJAJHCARE2025-09-30RelatedPartyTransactionDomain8BAJAJHCARE2025-07-012025-09-30RelatedPartyTransactionDomain9BAJAJHCARE2025-06-30RelatedPartyTransactionDomain9BAJAJHCARE2025-09-30RelatedPartyTransactionDomain9BAJAJHCARE2025-07-012025-09-30RelatedPartyTransactionDomain10BAJAJHCARE2025-06-30RelatedPartyTransactionDomain10BAJAJHCARE2025-09-30RelatedPartyTransactionDomain10iso4217:INRxbrli:pureiso4217:INRxbrli:shares539872BAJAJHCARENOTLISTEDINE411U01027BAJAJ HEALTHCARE LIMITEDMain BoardEquity2025-04-012026-03-312025-10-172025-10-13INRLakhsQuarterlySecond quarterSingle segmentPharmaceuticals2025-10-1716:25:002025-10-1716:47:00trueCash Flow IndirectNot applicabletruetrueNANAfalsetrue2025-02-11https://www.bajajhealth.com/policies/falsefalseDuring the quarter ended 30.09.2025, there is no default.2025-07-012025-09-30UnauditedStandalone14791490001652900014956780007480500000-12039000165087000555870007082100030855100013360570001596210000159621000035135000351350000124486000-17900000-4506000-133940000111092000187000011296200015791600053.953.88-0.42-0.413.533.470.00450.00510.03871 The above Financial Results of Bajaj Healthcare Limited the Company have been reviewed by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on 17 October 2025. These results have been subjected to limited review by the Statutory auditors who have expressed an unmodified review conclusion. <BR> <BR> 2 The above unaudited financial results for the quarter and half year ended 30 Sept 2025 have been prepared in accordance with the recognition and measurement principles laid down under Indian Accounting Standards Ind AS as prescribed under Section 133 of the Companies Act 2013 Act read with relevant rules issued there under and other accounting principles generally accepted in India in terms of Regulation 33 of the SEBI Listing <BR> obligations and disclosure requirements Regulations 2015 as amended. <BR> <BR> 3 The Company deals in pharmaceuticals products formulations and active pharmaceutical ingredients components which are interlinked and interdependent. Therefore the Company has identified only one reportable segment i.e. Pharmaceuticals. <BR> <BR> 4 In the year ended 31 March 2024 the Board of Directors had approved to sale/disposal of undertaking units on going concern basis situated at plot no. N92 L9.3 T30 MIDC Tarapur Taluka Boisar District Palghar Maharashtra and vacant industrial land situated at plot no. D2 CH 42 and D2 CH 43 Dahej industrial area GIDC Bharuch Gujarat which were acquired under SARFAESI ACT 2022 from Saraswat Bank and plot no.E62 and E63 MIDC Tarapur Taluka Boisar District Palghar Maharashtra. The approval of shareholders was obtained vide postal ballot. The Company has classified the assets and liabilities in relation to these units as Assets and liabilities held for sale/disposal under Ind AS 105 Non current Assets Held for Sale and Discontinued Operations. The results of the operation of these units have been presented separately on the statement of profit and loss as discontinued operations. Considering these assets are held for sale the assets have been recorded at their fair value on the date these assets has been classified as held for sale. Out of these one unit situated at plot no. N-92 was sold during the Quarter ended 31 March 2024. The total value of assets classified as held for sale represents lower of carrying value or fair value. <BR> <BR> The financial information from discontinued operations <BR> Particulars Quarter Ended Period ended Year ended <BR> 30 Sept 2025 30 June 2025 30 Sept 2024 30 Sept 2025 30 Sept 2024 31 March 2025 <BR> Unaudited Unaudited Unaudited Unaudited Unaudited Audited <BR> Total Income A 0.05 2.10 24.34 2.15 30.48 58.07 <BR> Total Expenses B 179.05 47.53 107.72 226.58 225.83 459.18 <BR> Loss before Tax from Discontinued Operations C = A - B -179.00 -45.43 -83.38 -224.43 -195.35 -401.11 <BR> Tax Credit from Discontinued Operations D -45.06 -11.43 -195.44 -56.49 -217.97 -57.78 <BR> Loss after Tax from Discontinued Operations E = C - D -133.94 -34.00 112.06 -167.94 22.62 -343.33 <BR> <BR> 5 The Board of Directors of the Company in their meeting held on 10 July 2024 and the shareholders of the company in Extra-Ordinary General Meeting EGM held on Wednesday 07 August 2024 through Video Conferencing VC Other Audio Visual Means OAVM approved the issue of 4044852 Equity Shares at Rs 338 per share including premium at Rs. 333 per share to Persons belonging to non-promoter category on preferential basis and the issue of convertible equity warrants 2079409 at Rs. 338 per warrant including premium at Rs. 333 per share to Persons belonging to promoter category as well as non-promoter category on preferential basis. The object of the issue is to repayment of term loan investment in capital expenditure and general corporate purposes. The Company has also obtained the in-principal approval of listing of equity shares from National Stock Exchange of India Ltd and BSE Ltd. On 19 September 2024 post approval from Board the Company has allotted 3984852 no. of equity shares and 2079409 convertible warrants and has also filed the relevant form with Registrar of Companies Mumbai. The uncalled amount of share warrants as at 30 September 2025 is Rs. 5271.30 lakhs and will be received within 18 months from the allotment date of 19 September 2024. <BR> <BR> 6 The fund raised through allotment of equity shares and convertible warrants under the preferential issue has been utilised for following activities. <BR> Particulars Rs in Lakhs <BR> Repayment & prepayment of secured/unsecured loans from bank/NBFC 15000.00 <BR> General corporate purposes 225.90 <BR> Total 15225.90 <BR> <BR> 7 In April 2025 the Company acquired Genrx Pharmaceuticals Private Limited (in Liquidation Genrx on a going concern basis. Genrx is an existing company incorporated under the provisions of the Companies Act 1956. The acquisition was made for a total consideration of Rs. 1085 lakhs. <BR> Subsequently on 3 June 2025 the Company filed an application with the Hon’ble National Company Law Tribunal NCLT Mumbai seeking certain reliefs and concessions necessary for the effective implementation of the acquisition and takeover of Genrx as a going concern which is pending with NCLT as on 30 September 2025. Hence Genrx has not been considered a subsidiary for consolidation purpose pending requisite approvals from the NCLT as control defined under Ind AS 110 Consolidated Financial Statements is not established. <BR> 2025-04-012025-09-30UnauditedStandalone2967512000253060002992818000144689900009499200030864900010784400012718600060237600026879460003048720000304872000058649000586490000246223000-22443000-5649000-167940000229429000374100023317000015791600057.87.63-0.53-0.527.277.110.00450.00470.0383Brokerage & Commission10098000Consumption of Stores Spares and Maintainence60603000Freight Forwarding & Transport34116000Insurance Expenses12532000Legal & Professional Expenses17354000Power and Fuel56579000Processing & Labour Charges47670000Travelling & Conveyence Expenses5308000Material Testing & Inspection Charges7496000Others56795000Brokerage & Commission20291000Consumption of Stores Spares and Maintainence124565000Freight Forwarding & Transport60671000Insurance Expenses18053000Legal & Professional Expenses38963000Power and Fuel113329000Processing & Labour Charges88235000Travelling & Conveyence Expenses16942000Material Testing & Inspection Charges14421000Others10690600021530870005834200000139340003078800000330000013707900013711200013469300037687600029048320001563076000023193680001197670002028400003419050002801324000036435200047287520007550980000838868200015791600047060180004863934000486393400056540300000040360000605763000664800000006722430001646873000581840007697420008279260002036250002678424000140090005235000002697668000154837000035247480008388682000The Company deals in pharmaceuticals products (formulations and active pharmaceutical ingredients components) which are interlinked and interdependent. Therefore, the Company has identified only one reportable segment i.e. Pharmaceuticals.107844000558010001989660000-22768000000000-2382490000127186000200000000000-21592000029930000000-22443000713000020246500050733700000054830000501854000081000000000000125000010984200000000000000000000029930000-11402000-1980010000000000096150001041010007794000010784400000-2101240009372900009372900026038000119767000Items that will not be reclassified to profit or loss25000002500000Items that will not be reclassified to profit or loss5000000500000063000012590000018700003741000Bajaj Healthcare Limited******Mrs. Nihita Bajaj Kumar******Daughter of Mr. Sajankumar Bajaj, Chairman & Managing Director & Sister of Ms. Namrata Bajaj, Whole-Time DirectorAny other transactionLegal & Professional FeesApproved by the Audit Committee500000535000427000Bajaj Healthcare Limited******Ms. Khushi Jain******Daughter of Mr. Anil Champalal Jain, Managing Director & Sister of Mr. Pakshal Anil Jain, Whole-Time DirectorAny other transactionLegal & Professional FeesApproved by the Audit Committee27000018000090000Bajaj Healthcare Limited******Mrs. Harshavi Pakshal Jain******Wife of Mr. Pakshal Jain, Whole-Time Director & Daughter-in-law of Mr. Anil Jain, Managing DirectorRemunerationNA95500000Bajaj Healthcare Limited******Taradevi Rameshwarlal Bajaj Charitable Trust******Charitable TrustAny other transactionCSR ExpensesApproved by the Audit Committee110000000Bajaj Healthcare Limited******Genrx Pharmaceuticals Private Limited******Body corporate directly/ indirectly owned by or significantly influenced by Director/s or their relativesAny other transactionOperating Expenses incurred by Bajaj on behalf of Genrx PharmaceuticalsApproved by the Audit Committee611900006119000The Company has acquired Genrx Pharmaceuticals Private Limited (in Liquidation) as a going concern through Sale Certificate dated 04.04.2025 & Possession Letter dated 05.04.2025. The status of Genrx Pharmaceuticals is in liquidation at ROC, hence there was no Board at the time of acquisition. Genrx Pharmaceuticals requires funding for their operational purposes. On 03.06.2025, the Company filed an application before the National Company Law Tribunal (NCLT), Mumbai, seeking certain reliefs and concessions necessary for the effective takeover of the Genrx Pharmaceuticals Private Limited (in Liquidation), Corporate Debtor and to complete the acquisition as a going concernBajaj Healthcare Limited******Mr. Sajankumar Bajaj******Chairman & Managing DirectorAdvanceApproved by the Audit Committee6000000000Advance06 monthsUnsecuredCorporate Business PurposesThe advance of Rs. 6,00,00,000 given by the Company to Mr. Sajankumar R. Bajaj who is a Promoter, Chairman & MD of the Company which was in the ordinary course of business and in accordance with the provisions of Section 185(3)(a)(i) of the Companies Act, 2013. The said advance was extended as a part of the conditions of service applicable to all employees of the Company, including senior management personnel, under the Company’s existing Employee Loan Policy, which provides for such financial assistance in accordance with the service terms. The said advance was repaid before completion of 6 months.Bajaj Healthcare Limited******Mr. Sajankumar Bajaj******Chairman & Managing DirectorRemunerationNA2124700000Bajaj Healthcare Limited******Mr. Anil Champalal Jain******Managing DirectorRemunerationNA1749700000Bajaj Healthcare Limited******Ms. Namrata Bajaj******Whole-Time DirectorRemunerationNA240600000Bajaj Healthcare Limited******Mr. Pakshal Jain******Son of Mr. Anil Champalal Jain, Managing DirectorRemunerationNA241500000112509000